Trials / Completed
CompletedNCT01068041
Effects of PH3 in Diabetic Nephropathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- PhytoHealth Corporation · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this clinical study is to evaluate the effectiveness and safety of PH3 for patients with diabetic nephropathy. The secondary objectives are to identify the optimal dosage for subsequent studies and to provide basis for the next confirmatory study in study design, endpoints, and study methodologies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PH3 | Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2014-07-01
- Completion
- 2015-09-01
- First posted
- 2010-02-12
- Last updated
- 2025-06-05
Locations
3 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01068041. Inclusion in this directory is not an endorsement.